Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.51 |
| ▸ | STS | P08842 | 5/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807945 | 0.87 | GPR119 (0.57) | GPR119STSNAMPT | |
| SCHEMBL1808102 | 0.85 | CACNA1B (0.48) | CACNA1B | |
| SCHEMBL1810708 | 0.85 | MMP13 (0.53) | GPR119STSTGFBR1 | |
| SCHEMBL1498436 | 0.85 | STS (0.58) | GPR119STSCACNA1BTGFBR1NAMPT | |
| SCHEMBL16818231 | 0.84 | GPR119 (0.54) | GPR119STSTGFBR1NAMPT | |
| SCHEMBL21626630 | 0.83 | GPR119 (0.60) | GPR119STSTGFBR1NAMPT | |
| SCHEMBL13947675 | 0.81 | GPR119 (0.59) | GPR119STSTGFBR1NAMPT | |
| SCHEMBL6793156 | 0.80 | GPR119 (0.50) | GPR119STSNAMPT | |
| SCHEMBL25864470 | 0.80 | GPR119 (0.52) | GPR119STSNAMPT | |
| SCHEMBL14655065 | 0.79 | HSD11B1 (0.63) | GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | GPR119 792/4885STS 296/4885CACNA1B 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.